Differentiation of opiate agonist and antagonist receptor binding by protein modifying reagents

H. Alexander Wilson, Gavril W. Pasternak, Solomon H Snyder

Research output: Contribution to journalArticle

Abstract

OPIATE antagonists differ from opiates only by the replacement of the N-methyl substituent with an N-allyl, N-cylcopropylmethyl or related group. Antagonists can reverse the pharmacological effects of opiates and so are important in the treatment of opiate overdose. Drugs that combine agonist and antagonist activities have potential as relatively nonaddicting analgesics. Although their mutual pharmacological antagonism indicates that they act at the same binding site, pharmacological discrepancies have prompted speculation that agonist and antagonist binding sites are separate1,2. Biochemical study of receptor binding3-16 has shown that although opiate agonists and antagonists compete for the same receptor3,4, there are differences in the way they interact with them7,10. Physiological concentrations of sodium enhance the binding of 3H-antagonists but reduce that of 3H-agonists. Sodium diminishes the ability of pure agonists to inhibit binding of 3H-naloxone to the receptor, but has little influence on inhibitory effects of pure antagonists and intermediate effects on those of combination agonist-antagonist drugs. The molecular basis for these differences, however, is unclear. As a first step in this direction we now report that binding of opiate receptors is much more sensitive to degradation by protein reagents which are known to modify sulphydryl groups than is binding by opiate antagonists. This suggests that distinct binding sites exist for agonists and antagonists, although they may both be on the same receptor.

Original languageEnglish (US)
Pages (from-to)448-450
Number of pages3
JournalNature
Volume253
Issue number5491
DOIs
StatePublished - 1975

Fingerprint

Opiate Alkaloids
Carrier Proteins
Binding Sites
Pharmacology
Sodium
Opioid Receptors
Pharmaceutical Preparations
Proteolysis
Analgesics

ASJC Scopus subject areas

  • General

Cite this

Differentiation of opiate agonist and antagonist receptor binding by protein modifying reagents. / Wilson, H. Alexander; Pasternak, Gavril W.; Snyder, Solomon H.

In: Nature, Vol. 253, No. 5491, 1975, p. 448-450.

Research output: Contribution to journalArticle

Wilson, H. Alexander ; Pasternak, Gavril W. ; Snyder, Solomon H. / Differentiation of opiate agonist and antagonist receptor binding by protein modifying reagents. In: Nature. 1975 ; Vol. 253, No. 5491. pp. 448-450.
@article{f40729af46b34ea781b8f50d560b71a7,
title = "Differentiation of opiate agonist and antagonist receptor binding by protein modifying reagents",
abstract = "OPIATE antagonists differ from opiates only by the replacement of the N-methyl substituent with an N-allyl, N-cylcopropylmethyl or related group. Antagonists can reverse the pharmacological effects of opiates and so are important in the treatment of opiate overdose. Drugs that combine agonist and antagonist activities have potential as relatively nonaddicting analgesics. Although their mutual pharmacological antagonism indicates that they act at the same binding site, pharmacological discrepancies have prompted speculation that agonist and antagonist binding sites are separate1,2. Biochemical study of receptor binding3-16 has shown that although opiate agonists and antagonists compete for the same receptor3,4, there are differences in the way they interact with them7,10. Physiological concentrations of sodium enhance the binding of 3H-antagonists but reduce that of 3H-agonists. Sodium diminishes the ability of pure agonists to inhibit binding of 3H-naloxone to the receptor, but has little influence on inhibitory effects of pure antagonists and intermediate effects on those of combination agonist-antagonist drugs. The molecular basis for these differences, however, is unclear. As a first step in this direction we now report that binding of opiate receptors is much more sensitive to degradation by protein reagents which are known to modify sulphydryl groups than is binding by opiate antagonists. This suggests that distinct binding sites exist for agonists and antagonists, although they may both be on the same receptor.",
author = "Wilson, {H. Alexander} and Pasternak, {Gavril W.} and Snyder, {Solomon H}",
year = "1975",
doi = "10.1038/253448a0",
language = "English (US)",
volume = "253",
pages = "448--450",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "5491",

}

TY - JOUR

T1 - Differentiation of opiate agonist and antagonist receptor binding by protein modifying reagents

AU - Wilson, H. Alexander

AU - Pasternak, Gavril W.

AU - Snyder, Solomon H

PY - 1975

Y1 - 1975

N2 - OPIATE antagonists differ from opiates only by the replacement of the N-methyl substituent with an N-allyl, N-cylcopropylmethyl or related group. Antagonists can reverse the pharmacological effects of opiates and so are important in the treatment of opiate overdose. Drugs that combine agonist and antagonist activities have potential as relatively nonaddicting analgesics. Although their mutual pharmacological antagonism indicates that they act at the same binding site, pharmacological discrepancies have prompted speculation that agonist and antagonist binding sites are separate1,2. Biochemical study of receptor binding3-16 has shown that although opiate agonists and antagonists compete for the same receptor3,4, there are differences in the way they interact with them7,10. Physiological concentrations of sodium enhance the binding of 3H-antagonists but reduce that of 3H-agonists. Sodium diminishes the ability of pure agonists to inhibit binding of 3H-naloxone to the receptor, but has little influence on inhibitory effects of pure antagonists and intermediate effects on those of combination agonist-antagonist drugs. The molecular basis for these differences, however, is unclear. As a first step in this direction we now report that binding of opiate receptors is much more sensitive to degradation by protein reagents which are known to modify sulphydryl groups than is binding by opiate antagonists. This suggests that distinct binding sites exist for agonists and antagonists, although they may both be on the same receptor.

AB - OPIATE antagonists differ from opiates only by the replacement of the N-methyl substituent with an N-allyl, N-cylcopropylmethyl or related group. Antagonists can reverse the pharmacological effects of opiates and so are important in the treatment of opiate overdose. Drugs that combine agonist and antagonist activities have potential as relatively nonaddicting analgesics. Although their mutual pharmacological antagonism indicates that they act at the same binding site, pharmacological discrepancies have prompted speculation that agonist and antagonist binding sites are separate1,2. Biochemical study of receptor binding3-16 has shown that although opiate agonists and antagonists compete for the same receptor3,4, there are differences in the way they interact with them7,10. Physiological concentrations of sodium enhance the binding of 3H-antagonists but reduce that of 3H-agonists. Sodium diminishes the ability of pure agonists to inhibit binding of 3H-naloxone to the receptor, but has little influence on inhibitory effects of pure antagonists and intermediate effects on those of combination agonist-antagonist drugs. The molecular basis for these differences, however, is unclear. As a first step in this direction we now report that binding of opiate receptors is much more sensitive to degradation by protein reagents which are known to modify sulphydryl groups than is binding by opiate antagonists. This suggests that distinct binding sites exist for agonists and antagonists, although they may both be on the same receptor.

UR - http://www.scopus.com/inward/record.url?scp=0016436120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016436120&partnerID=8YFLogxK

U2 - 10.1038/253448a0

DO - 10.1038/253448a0

M3 - Article

C2 - 46111

AN - SCOPUS:0016436120

VL - 253

SP - 448

EP - 450

JO - Nature

JF - Nature

SN - 0028-0836

IS - 5491

ER -